Description

Elacridar Hcl is a potent and selective third-generation P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) inhibitor. This compound is critical for enhancing the bioavailability and efficacy of co-administered chemotherapeutic agents by overcoming multidrug resistance (MDR) in cancer cells. It is an essential research tool and pharmaceutical intermediate for oncology R&D, formulation development, and preclinical studies targeting improved drug delivery and therapeutic outcomes.

Application

• Oncology Research: Used as a key pharmacological tool to study and overcome P-gp and BCRP-mediated multidrug resistance in various cancer cell lines and animal models.
• Drug Formulation Development: Incorporated into novel drug delivery systems, such as nanoparticles and liposomes, to enhance the penetration and retention of chemotherapeutics.
• Pharmacokinetic Studies: Employed in ADME (Absorption, Distribution, Metabolism, Excretion) research to investigate the role of efflux transporters on drug bioavailability and tissue distribution.
• Preclinical Candidate Evaluation: Serves as a positive control or co-administered agent in efficacy studies for new anticancer drug candidates.
• Blood-Brain Barrier (BBB) Research: Applied in neuroscience and oncology research to inhibit efflux transporters at the BBB, potentially increasing central nervous system exposure to therapeutics.
• Reference Standard: Used as a high-purity analytical standard in quality control laboratories for method development and validation.

Basic Information

Product Name	Elacridar Hcl
CAS No.	143851-98-3
Molecular Formula	C34H34F2N4O4 • HCl
Molecular Weight	629.12 g/mol (free base: 592.66)
Synonyms	GF120918; GW120918; N-(4-[2-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide hydrochloride; Elacridar hydrochloride; P-gp/BCRP Inhibitor III
EINECS	Contact for details

Quality Control

Our Elacridar Hcl is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including HPLC for purity, identity confirmation by IR and MS, and residual solvent analysis, to ensure it meets the stringent requirements for pharmaceutical research. Certificates of Analysis (COA) with detailed chromatographic data are provided for every shipment.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at 2-8°C or as indicated on the label/Certificate of Analysis. Due to its hygroscopic nature, the container should be kept tightly sealed in a desiccated environment to maintain stability and purity.

Specification

Item	Specification
Appearance	Yellow to orange solid powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥98.0%
Water Content (KF)	≤1.0%
Residue on Ignition	≤0.1%
Heavy Metals	≤20 ppm
Single Unknown Impurity (HPLC)	≤0.5%
Total Impurities (HPLC)	≤2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.